The value of pretest probability and modified clinical pulmonary infection score to diagnose ventilator-associated pneumonia☆
Abstract
Purpose
The aim of the study was to assess the utility of pretest probability and modified clinical pulmonary infection score CPIS in the diagnosis of late-onset ventilator-associated pneumonia (VAP).
Materials and Methods
In 740 adults enrolled in a multicenter randomized trial, intensivists prospectively rated the pretest probability of VAP as low, moderate, or high based on their clinical judgment. The modified CPIS was calculated without considering culture results. Ventilator-associated pneumonia diagnosis was determined by 2 adjudicators using standardized definitions. We analyzed the relationship between pretest likelihood, CPIS, and VAP diagnosis.
Results
Among the 739 patients analyzed, 14.5%, 39.6%, and 45.9% had low, moderate, and high pretest probability of VAP. Patients with high pretest probability had a lower PaO2/FiO2 ratio and a larger volume of secretions. High or moderate vs low pretest probability had high sensitivity (0.88; 95% confidence interval [CI], 0.87-0.89) and positive predictive value (0.87; 95% CI, 0.86-0.88) but low specificity (0.27; 95% CI, 0.21-0.35) and negative predictive value (0.29; 95% C,: 0.22-0.37) for the diagnosis of VAP. Therefore, 71% of patients who had a low pretest probability were actually infected (1 − negative predictive value). The area under the receiver operating characteristic curve for the modified CPIS was not significant (0.47; 95% CI, 0.42-0.53), meaning that no score threshold was clinically useful.
Conclusions
Pretest probability and a modified CPIS, which excludes culture results, are of limited utility in the diagnosis of late-onset VAP.
Keywords: Clinical pulmonary infection score, Pretest probability, Pneumonia
To access this article, please choose from the options below
☆ This study was supported by grants from the Canadian Institutes of Health Research and Physicians' Services Incorporated of Ontario, and by unrestricted grants from AstraZeneca and Bayer. François Lauzier and Annie Ruest are supported by a postdoctoral fellowship award from Université Laval. Annie Ruest is supported by a postdoctoral fellowship award from the Fonds de Recherche en Santé du Québec. Deborah Cook holds a Research Chair of the Canadian Institutes of Health Research.
PII: S0883-9441(08)00021-X
doi:10.1016/j.jcrc.2008.01.006
© 2008 Elsevier Inc. All rights reserved.
